JP2021503485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503485A5 JP2021503485A5 JP2020527828A JP2020527828A JP2021503485A5 JP 2021503485 A5 JP2021503485 A5 JP 2021503485A5 JP 2020527828 A JP2020527828 A JP 2020527828A JP 2020527828 A JP2020527828 A JP 2020527828A JP 2021503485 A5 JP2021503485 A5 JP 2021503485A5
- Authority
- JP
- Japan
- Prior art keywords
- sugar
- preparation according
- stabilizer
- concentration
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024129687A JP2024160287A (ja) | 2017-11-17 | 2024-08-06 | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762587733P | 2017-11-17 | 2017-11-17 | |
| US62/587,733 | 2017-11-17 | ||
| US201862618904P | 2018-01-18 | 2018-01-18 | |
| US62/618,904 | 2018-01-18 | ||
| PCT/US2018/061644 WO2019099921A2 (en) | 2017-11-17 | 2018-11-16 | Vegfr-fc fusion protein formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024129687A Division JP2024160287A (ja) | 2017-11-17 | 2024-08-06 | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503485A JP2021503485A (ja) | 2021-02-12 |
| JP2021503485A5 true JP2021503485A5 (https=) | 2021-12-09 |
| JP7536640B2 JP7536640B2 (ja) | 2024-08-20 |
Family
ID=65041879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527828A Active JP7536640B2 (ja) | 2017-11-17 | 2018-11-16 | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
| JP2024129687A Pending JP2024160287A (ja) | 2017-11-17 | 2024-08-06 | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024129687A Pending JP2024160287A (ja) | 2017-11-17 | 2024-08-06 | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12156900B2 (https=) |
| EP (1) | EP3709971A2 (https=) |
| JP (2) | JP7536640B2 (https=) |
| AU (2) | AU2018368466B2 (https=) |
| CA (1) | CA3082899A1 (https=) |
| MA (1) | MA50908A (https=) |
| MX (2) | MX2020005170A (https=) |
| WO (1) | WO2019099921A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020005170A (es) | 2017-11-17 | 2020-10-16 | Amgen Inc | Formulaciones de proteinas de fusion vegfr-fc. |
| AU2019212622B2 (en) | 2018-01-26 | 2024-05-23 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| EP3761953A1 (en) | 2018-03-08 | 2021-01-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| WO2020055123A1 (ko) | 2018-09-10 | 2020-03-19 | 삼성바이오에피스 주식회사 | 단백질을 포함하는 액상 조성물 |
| WO2021050687A1 (en) * | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| CA3190325A1 (en) * | 2020-07-31 | 2022-02-03 | Celltrion Inc. | Stable pharmaceutical preparation |
| US20240166718A1 (en) * | 2021-02-17 | 2024-05-23 | Arecor Limited | Aqueous composition of an engineered protein construct comprising an fc domain |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| WO2025227916A1 (zh) | 2024-04-29 | 2025-11-06 | 齐鲁制药有限公司 | 包含阿柏西普和其变体的组合物以及相关方法和应用 |
| US12240888B1 (en) | 2024-04-29 | 2025-03-04 | QILU Pharmaceutical, Co., Ltd. | Composition comprising aflibercept and a variant thereof, and related methods and uses |
| JP2026054929A (ja) | 2024-09-17 | 2026-03-30 | キオクシア株式会社 | メモリシステムおよび制御方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1478394T1 (sl) | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CN103816115B (zh) | 2010-08-31 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| ES2985784T3 (es) | 2011-11-18 | 2024-11-07 | Regeneron Pharma | Micropartículas de proteínas recubiertas con polímeros para formulaciones de liberación prolongada para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares |
| JP6313712B2 (ja) | 2011-12-21 | 2018-04-18 | アムジエン・インコーポレーテツド | 新生児Ｆｃ受容体への結合を強化された変異型Ｆｃポリペプチド |
| CN103212075B (zh) | 2012-01-19 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| AU2013267310A1 (en) | 2012-06-01 | 2014-12-11 | Ophthotech Corporation | Compositions comprising an anti-PDGF aptamer and a VEGF antagonist |
| UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| WO2014078627A1 (en) | 2012-11-19 | 2014-05-22 | Merck Sharp & Dohme Corp. | Liquid formulations for tnfr:fc fusion proteins |
| CA2926853C (en) | 2013-10-18 | 2022-04-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
| CN105435222B (zh) | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| EP3362041B1 (en) | 2015-10-16 | 2026-04-08 | Regeneron Pharmaceuticals, Inc. | Stable protein compositions |
| ES2981791T3 (es) | 2015-12-16 | 2024-10-10 | Regeneron Pharma | Composiciones y métodos para fabricar micropartículas de proteína |
| US10576128B2 (en) | 2016-01-26 | 2020-03-03 | Formycon Ag | Liquid formulation of a VEGF antagonist |
| EP3436473A4 (en) | 2016-03-29 | 2019-10-23 | Navya Biologicals Pvt. Ltd. | METHOD FOR PURIFYING FC FUSION PROTEINS |
| KR101685532B1 (ko) | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| EP3518971A4 (en) | 2016-09-28 | 2020-05-13 | Board Of Regents, The University Of Texas System | ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF |
| PT3528787T (pt) | 2016-10-21 | 2026-03-11 | Amgen Inc | Formulações farmacêuticas e métodos para produzir as mesmas |
| JP7116059B2 (ja) | 2016-11-21 | 2022-08-09 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | アフリベルセプト製剤及びその使用 |
| CR20190291A (es) | 2016-12-23 | 2019-11-05 | Serum Institute Of India Pvt Ltd | Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos |
| KR101861163B1 (ko) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| US20200255496A1 (en) | 2017-09-18 | 2020-08-13 | Amgen Inc. | Vegfr-fc fusion protein formulations |
| CN107595765A (zh) | 2017-09-22 | 2018-01-19 | 沈阳兴齐眼药股份有限公司 | 一种眼用缓释药物递送系统及其制备方法 |
| MX2020005170A (es) | 2017-11-17 | 2020-10-16 | Amgen Inc | Formulaciones de proteinas de fusion vegfr-fc. |
| MY202872A (en) | 2017-11-20 | 2024-05-28 | Just Evotec Biologics Inc | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| WO2019124946A1 (ko) | 2017-12-22 | 2019-06-27 | 삼성바이오에피스 주식회사 | Vegf 길항제를 포함하는 액상 조성물 |
| EP3761953A1 (en) * | 2018-03-08 | 2021-01-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| WO2020055123A1 (ko) | 2018-09-10 | 2020-03-19 | 삼성바이오에피스 주식회사 | 단백질을 포함하는 액상 조성물 |
| US20210353713A1 (en) | 2018-10-26 | 2021-11-18 | Amgen Inc. | Formulations comprising a tris buffer and a protein |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| GB201911461D0 (en) | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
| WO2021050687A1 (en) | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
-
2018
- 2018-11-16 MX MX2020005170A patent/MX2020005170A/es unknown
- 2018-11-16 MA MA050908A patent/MA50908A/fr unknown
- 2018-11-16 CA CA3082899A patent/CA3082899A1/en active Pending
- 2018-11-16 US US16/764,463 patent/US12156900B2/en active Active
- 2018-11-16 AU AU2018368466A patent/AU2018368466B2/en active Active
- 2018-11-16 EP EP18836718.9A patent/EP3709971A2/en active Pending
- 2018-11-16 WO PCT/US2018/061644 patent/WO2019099921A2/en not_active Ceased
- 2018-11-16 JP JP2020527828A patent/JP7536640B2/ja active Active
-
2020
- 2020-07-13 MX MX2025004779A patent/MX2025004779A/es unknown
-
2024
- 2024-07-31 AU AU2024205240A patent/AU2024205240A1/en active Pending
- 2024-08-06 JP JP2024129687A patent/JP2024160287A/ja active Pending
- 2024-11-25 US US18/959,137 patent/US20250082726A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503485A5 (https=) | ||
| ES2759931T3 (es) | Formulaciones líquidas farmacéuticas estables de la proteína de fusión TNFR:Fc | |
| RU2011127913A (ru) | Составы, содержащие антитела | |
| JP2020138981A5 (https=) | ||
| FI3408295T3 (fi) | Bispesifisiä vasta-ainekonstrukteja käsittävä farmaseuttinen koostumus | |
| JP2009540001A5 (https=) | ||
| RU2009101226A (ru) | Составы антагониста vegf, подходящие для интравитреального введения | |
| JP2009524595A5 (https=) | ||
| JP2016520075A5 (https=) | ||
| CN101312744A (zh) | 免疫球蛋白融合蛋白制剂 | |
| JP2010068806A5 (https=) | ||
| JP2016065060A5 (https=) | ||
| RU2015111341A (ru) | Композиции антитела и белка | |
| JP2013079270A5 (https=) | ||
| JP2021521171A5 (https=) | ||
| JP2019509311A5 (https=) | ||
| JP3105494B2 (ja) | 蛋白質を安定化するための改良された方法 | |
| JP2012136518A5 (https=) | ||
| RU2019116756A (ru) | Жидкая фармацевтическая композиция | |
| JP2017514868A5 (https=) | ||
| RU2019109975A (ru) | Способы очистки антител | |
| JP2015535237A5 (https=) | ||
| JP2019501920A5 (https=) | ||
| JP2016508143A5 (https=) | ||
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela |